Analysts at investment firm TD Cowen upgrade US drug companiesmodena(Moderna)’s stock rating was upgraded to “Outperform” from “Market Underperform”, and remains optimistic that Moderna will become the RSV (respiratory syncytial virus) vaccine market leader.
TD Cowen analysts said in a report that Moderna’s performance in the near future will no longer depend on a new wave of new coronavirus variants, but on RSV vaccines andflu vaccines,
After the outbreak of the New Crown pandemic, Moderna became a household name with their mRNA vaccine, and they are currently trying to continue their growth momentum in the post-pandemic period. The mRNA technology directs cells in the body to make proteins that initiate an immune response to fight a particular disease.
Cowen reported that key industry players believe that the RSV vaccine market will be shaped by Moderna,pfizer(Pfizer), GlaxoSmithKline (GSK) “three heroes” position. The RSV vaccine infects the lungs and airways, causing mild cold-like symptoms. Most people recover within a week or two, but RSV can also cause severe illness, especially in infants and the elderly.
Cowen reported that Moderna’s RSV vaccine performed well in clinical trials and was well tolerated by patients. The vaccine can prevent people over age 60 with two or three symptoms from becoming infected with RSV, with a protection rate of 83.7%; Against lower respiratory tract infections that cause three or more symptoms, the protection rate is 82.4%.
Moderna’s vaccine was just as effective as GlaxoSmithKline’s. The US Food and Drug Administration (FDA) reviewed the data on the GlaxoSmithKline vaccine and found that it was 83% effective in preventing lower respiratory tract disease caused by RSV in clinical trials.
But GlaxoSmithKline and Pfizer are still a step ahead of Moderna. Earlier this month, an FDA independent advisory panel recommended that GlaxoSmithKline and Pfizer’s RSV vaccine be given to adults over age 60.